CRISPR THERAPEUTICS AG Financing Cash Flow
CRISPR THERAPEUTICS AG (CRSP) reported Financing Cash Flow of $599.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $7.18M, a 217.98% increase year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $591.91M, a 5490.37% increase year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $116.41M, a 589.82% increase year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $296.77M, a 2978.49% increase year-over-year.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for fiscal 2025 was $426.03M, a 28.33% increase from fiscal 2024.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for fiscal 2024 was $331.98M, a 429.78% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for fiscal 2023 was $62.66M, a 62.38% increase from fiscal 2022.
- CRISPR THERAPEUTICS AG net cash provided by (used in) financing activities for fiscal 2022 was $38.59M, a 84.62% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $599.09M 10-Q · filed 2026-08-03 | $715.50M derived: sum of 3 quarters · filed 2026-08-03 | $1.01B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $591.91M 10-Q · filed 2026-05-04 | $708.32M derived: sum of 2 quarters · filed 2026-05-04 | $1.01B derived: sum of 3 quarters · filed 2026-05-04 | $1.01B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $116.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $413.18M derived: sum of 2 quarters · filed 2026-02-12 | $415.44M derived: sum of 3 quarters · filed 2026-08-03 | $426.03M 10-K · filed 2026-02-12 |
| 2025-09-30 | $296.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $299.02M derived: sum of 2 quarters · filed 2026-08-03 | $309.61M 10-Q · filed 2025-11-10 | $326.49M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $12.85M 10-Q · filed 2026-08-03 | $29.72M derived: sum of 3 quarters · filed 2026-08-03 | $39.36M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $10.59M 10-Q · filed 2026-05-04 | $27.46M derived: sum of 2 quarters · filed 2026-05-04 | $37.10M derived: sum of 3 quarters · filed 2026-05-04 | $36.64M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $16.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $26.52M derived: sum of 2 quarters · filed 2026-02-12 | $26.05M derived: sum of 3 quarters · filed 2026-02-12 | $331.98M 10-K · filed 2026-02-12 |
| 2024-09-30 | $9.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $9.17M derived: sum of 2 quarters · filed 2025-11-10 | $315.11M 10-Q · filed 2025-11-10 | $354.05M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$466.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $305.47M 10-Q · filed 2025-08-04 | $344.41M derived: sum of 3 quarters · filed 2026-02-12 | $345.96M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $305.93M 10-Q · filed 2025-05-06 | $344.87M derived: sum of 2 quarters · filed 2026-02-12 | $346.43M derived: sum of 3 quarters · filed 2026-02-12 | $363.19M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $38.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $40.49M derived: sum of 2 quarters · filed 2026-02-12 | $57.26M derived: sum of 3 quarters · filed 2026-02-12 | $62.66M 10-K · filed 2026-02-12 |
| 2023-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $18.32M derived: sum of 2 quarters · filed 2024-11-05 | $23.73M 10-Q · filed 2024-11-05 | $26.20M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $16.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $22.17M 10-Q · filed 2024-08-05 | $24.65M derived: sum of 3 quarters · filed 2025-02-11 | $39.76M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $5.40M 10-Q · filed 2024-05-08 | $7.88M derived: sum of 2 quarters · filed 2025-02-11 | $22.99M derived: sum of 3 quarters · filed 2025-02-11 | $33.35M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $17.59M derived: sum of 2 quarters · filed 2025-02-11 | $27.94M derived: sum of 3 quarters · filed 2025-02-11 | $38.59M 10-K · filed 2025-02-11 |
| 2022-09-30 | $15.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $25.46M derived: sum of 2 quarters · filed 2023-11-06 | $36.11M 10-Q · filed 2023-11-06 | $42.41M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $10.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $21.00M 10-Q · filed 2023-08-07 | $27.30M derived: sum of 3 quarters · filed 2024-02-21 | $37.51M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $10.65M 10-Q · filed 2022-05-09 | $16.95M derived: sum of 2 quarters · filed 2024-02-21 | $27.16M derived: sum of 3 quarters · filed 2024-02-21 | $35.60M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $16.51M derived: sum of 2 quarters · filed 2024-02-21 | $24.95M derived: sum of 3 quarters · filed 2024-02-21 | $250.94M 10-K · filed 2024-02-21 |
| 2021-09-30 | $10.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $18.66M derived: sum of 2 quarters · filed 2022-11-01 | $244.65M 10-Q · filed 2022-11-01 | $657.27M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $8.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $234.43M 10-Q · filed 2022-08-08 | $647.06M derived: sum of 3 quarters · filed 2023-02-21 | $1.16B derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $225.99M 10-Q · filed 2022-05-09 | $638.62M derived: sum of 2 quarters · filed 2023-02-21 | $1.15B derived: sum of 3 quarters · filed 2023-02-21 | $1.24B derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $412.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $925.51M derived: sum of 2 quarters · filed 2023-02-21 | $1.02B derived: sum of 3 quarters · filed 2023-02-21 | $1.02B 10-K · filed 2023-02-21 |
| 2020-09-30 | $512.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $602.39M derived: sum of 2 quarters · filed 2021-11-03 | $603.52M 10-Q · filed 2021-11-03 | $908.24M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $89.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $90.64M 10-Q · filed 2021-07-29 | $395.36M derived: sum of 3 quarters · filed 2022-02-15 | $466.24M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $1.13M 10-Q · filed 2021-04-27 | $305.85M derived: sum of 2 quarters · filed 2022-02-15 | $376.74M derived: sum of 3 quarters · filed 2022-02-15 | $406.39M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $304.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $375.60M derived: sum of 2 quarters · filed 2022-02-15 | $405.26M derived: sum of 3 quarters · filed 2022-02-15 | $430.98M 10-K · filed 2022-02-15 |
| 2019-09-30 | $70.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $100.54M derived: sum of 2 quarters · filed 2020-10-28 | $126.27M 10-Q · filed 2020-10-28 | $125.00M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $29.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $55.38M 10-Q · filed 2020-07-27 | $54.11M derived: sum of 3 quarters · filed 2021-02-16 | $242.33M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $25.73M 10-Q · filed 2020-04-28 | $24.46M derived: sum of 2 quarters · filed 2021-02-16 | $212.68M derived: sum of 3 quarters · filed 2021-02-16 | $216.41M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $186.95M derived: sum of 2 quarters · filed 2021-02-16 | $190.68M derived: sum of 3 quarters · filed 2021-02-16 | $315.93M 10-K · filed 2021-02-16 |
| 2018-09-30 | $188.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $191.95M derived: sum of 2 quarters · filed 2019-10-28 | $317.20M 10-Q · filed 2019-10-28 | $318.49M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $128.98M 10-Q · filed 2019-07-29 | $130.26M derived: sum of 3 quarters · filed 2020-02-12 | $130.87M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $125.25M 10-Q · filed 2019-04-29 | $126.53M derived: sum of 2 quarters · filed 2020-02-12 | $127.14M derived: sum of 3 quarters · filed 2020-02-12 | |
| 2017-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $1.89M derived: sum of 2 quarters · filed 2020-02-12 | $2.61M 10-K · filed 2020-02-12 | |
| 2017-09-30 | $609.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $1.32M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $715.00K 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $183.22M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |